By Sheeba M. | April 17, 2026
Canadian LPs Pivot to U.S. Hemp Markets as Domestic Sales Stall
Canada’s legal cannabis market has hit a ceiling. After years of explosive growth following recreational legalization in 2018, domestic sales have plateaued around CAD $4 billion annually, with little catalyst for expansion. For Canadian licensed producers, the math is simple: grow internationally or shrink domestically.
The U.S. Hemp Opportunity
The 2018 Farm Bill opened a backdoor for Canadian companies to participate in the U.S. cannabis-adjacent market without violating federal law. Hemp-derived CBD products fall outside the Controlled Substances Act, creating a legal pathway for international operators. Organigram has been particularly aggressive in this strategy, acquiring U.S.-based wellness brands and distribution relationships.
The U.S. hemp market—encompassing CBD, minor cannabinoids like delta-8 THC, and wellness applications—is estimated at $20-25 billion annually. Unlike Canadian recreational cannabis, which remains heavily taxed and regulated, hemp-derived products move through conventional retail channels with standard supply chain logistics.
Regulatory Tightrope
The strategy is not without risk. The FDA has yet to establish a clear regulatory framework for CBD in food and beverages, creating uncertainty. Additionally, any operator perceived as exploiting regulatory gray areas faces potential enforcement action that could disrupt supply chains overnight.
Canopy Growth has attempted to straddle both markets with its acquisition of U.S. hemp operator Biosphere, but integration challenges have delayed projected synergies. Industry observers suggest the company may need to write down its U.S. assets if the FDA fails to clarify CBD regulations by late 2026.
Market Share Implications
If the U.S. hemp-derived THC market matures—with federal clarity on minor cannabinoids—Canadian LPs with established supply chains and manufacturing expertise could quickly capture significant share. Companies with U.S. presence today are essentially reserving seats at a table that may not be served for another 12-24 months.
Verano and domestic U.S. operators have largely ignored the hemp channel to focus on higher-margin state-licensed cannabis. This strategic choice may prove costly if federal reform opens floodgates for hemp-derived THC products competing directly with medical and recreational cannabis.
Sources
- Leafly Canada Market Report — Canadian cannabis sales data and projections
- Bloomberg: U.S. Hemp Market Analysis — Market sizing and competitive dynamics
- FDA CBD Regulatory Framework — Federal stance on hemp-derived products
Track cannabis stocks with the Weedstock Real-Time Tracker